ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
ProPhase Labs, Inc. (PRPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number of 4.07 million shares as of 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber · last filed 2022-05-13
- 2022-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 4.07M shares.
- 2017-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 361.00K shares.
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1.70M shares.
- 2015-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1.71M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number as first filed |
|---|---|---|
| 2022-03-31 | 4.07M shares 10-Q · filed 2022-05-13 | |
| 2017-12-31 | 361.00K shares 10-K/A · filed 2018-08-20 | |
| 2016-12-31 | 1.70M shares 10-K/A · filed 2018-08-20 | |
| 2015-12-31 | 1.71M shares 10-K/A · filed 2018-08-20 | |
| 2014-12-31 | 1.48M shares 10-K · filed 2017-02-24 | |
| 2013-12-31 | 1.08M shares 10-K · filed 2016-03-29 | 754.00K shares 10-K · filed 2014-03-27 |
| 2012-12-31 | 588.00K shares 10-K · filed 2015-03-27 | |
| 2011-12-31 | 376.00K shares 10-K · filed 2014-03-27 | |
| 2010-12-31 | 363.00K shares 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |